Constans Joël, Germain Christine, Gosse Philippe, Taillard Jacques, Tiev Kiet, Delevaux Isabelle, Mouthon Luc, Schmidt Claude, Granel Florence, Soria Pascale, Lifermann François, Etienne Gabriel, Bonnet Fabrice, Zoulim Karim, Farge-Bancel Dominique, Marie Isabelle, Allanore Yannick, Cabane Jean, Amonchot Alain, Macquin-Mavier Isabelle, Saves Marianne, Zannad Faiez, Conri Claude
Vascular and Internal Medicine Unit, CHU Bordeaux, Paris, France.
J Hypertens. 2007 Sep;25(9):1900-6. doi: 10.1097/HJH.0b013e328244e1eb.
The ERAMS study addressed the value of arterial stiffness in predicting the severity of systemic sclerosis.
ERAMS was a prospective multicentre cohort study including patients with definite systemic sclerosis. Arterial stiffness was measured by the standardized non-invasive QKd 100-60 method. Clinical evaluation, biological measurements, functional respiratory tests and cardiac Doppler echography were performed at inclusion then each year until 3 years' follow-up was completed. Progression was defined as mild (articulations, muscle, oesophagus or skin involvement) or severe (lung, heart or kidney involvement) by a critical event committee. The prediction of severe progression was studied for QKd 100-60 as well as clinical and biological data at baseline by univariate and multivariate analysis.
Ninety-nine patients were included (81 women, 18 men, mean age 57 years, standard deviation 12.5). Although their blood pressure profile was normal, half the patients had increased arterial stiffness (QKd 100-60<200 ms). There was a significant relationship between age-adjusted arterial stiffness and decrease in carbon dioxide diffusion (P<0.03) or haemoglobin rate (P<0.01). By univariate analysis, severe progression after 3 years was predicted by age (P=0.04), lung involvement (P=0.04), diffusion of lung carbon oxide (DLCO) (P<0.01), skin score (P=0.02), haemoglobin (P<0.01) and baseline Qkd 100-60 divided into two classes according to the median (P<0.01). By multivariate analysis, only haemoglobin rate [odds ratio (OR) 0.4, 95% confidence interval (CI) 0.2-0.9] and QKd 100-60 (OR 19.6, 95% CI 1.2-308.2) predicted severe progression of systemic sclerosis.
The measurement of arterial stiffness by the QKd method is a useful objective method for assessing the prognosis of systemic sclerosis independently from other data.
ERAMS研究探讨了动脉僵硬度在预测系统性硬化症严重程度方面的价值。
ERAMS是一项前瞻性多中心队列研究,纳入了确诊为系统性硬化症的患者。采用标准化非侵入性QKd 100 - 60方法测量动脉僵硬度。在纳入研究时进行临床评估、生物学检测、功能性呼吸测试和心脏多普勒超声检查,之后每年进行一次,直至完成3年随访。由一个关键事件委员会将病情进展定义为轻度(关节、肌肉、食管或皮肤受累)或重度(肺、心脏或肾脏受累)。通过单因素和多因素分析,研究了QKd 100 - 60以及基线时的临床和生物学数据对重度病情进展的预测情况。
共纳入99例患者(81名女性,18名男性,平均年龄57岁,标准差12.5)。尽管他们的血压水平正常,但一半患者的动脉僵硬度增加(QKd 100 - 60 < 200毫秒)。年龄校正后的动脉僵硬度与二氧化碳弥散降低(P < 0.03)或血红蛋白率降低(P < 0.01)之间存在显著相关性。单因素分析显示,3年后的重度病情进展可由年龄(P = 0.04)、肺部受累(P = 0.04)、肺一氧化碳弥散量(DLCO)(P < 0.01)、皮肤评分(P = 0.02)、血红蛋白(P < 0.01)以及根据中位数将基线Qkd 100 - 60分为两类(P < 0.01)预测。多因素分析显示,只有血红蛋白率[比值比(OR)0.4,95%置信区间(CI)0.2 - 0.9]和QKd 100 - 60(OR 19.6,95% CI 1.2 - 308.2)可预测系统性硬化症的重度病情进展。
采用QKd方法测量动脉僵硬度是一种有用的客观方法,可独立于其他数据评估系统性硬化症的预后。